Writing Group Disclosures
| Writing Group Member | Employment | Research Grant | Other Research Support | Speakers’ Bureau/ Honoraria | Expert Witness | Ownership Interest | Consultant/ Advisory Board | Other |
|---|---|---|---|---|---|---|---|---|
| Umberto Campia | Brigham and Women’s Hospital–Harvard Medical School | None | None | None | None | None | None | None |
| Javid J. Moslehi | Vanderbilt University Medical Center | Bristol-Myers Squibb†; NIH (R56 HL141466)†; Pfizer† | None | None | None | None | Bristol-Myers Squibb*; Ipsen*; Myokardia*; Novartis*; Pfizer*; Regeneron*; Takeda* | None |
| Laleh Amiri-Kordestani | FDA | None | None | None | None | None | None | None |
| Ana Barac | Medstar Heart and Vascular Institute, Medstar Washington Hospital Center | Genentech (serves as a cardiology PI on an investigator-initiated study supported by Genentech)* | None | None | None | None | None | None |
| Joshua A. Beckman | Vanderbilt University | Bayer (DSMB)†; Novartis (DSMB)* | None | None | None | None | AstraZeneca*; Boehringer Ingelheim*; Bristol Myers Squibb*; Merck*; Sonofi* | None |
| David D. Chism | Vanderbilt University Medical Center | None | None | None | None | None | None | None |
| Paul Cohen | Rockefeller University Laboratory of Molecular Metabolism | None | None | None | None | None | None | None |
| John D. Groarke | Brigham and Women’s Hospital | Amgen† | None | None | None | None | None | None |
| Joerg Herrmann | Mayo Clinic Rochester | Amgen† | None | None | None | None | None | None |
| Carolyn M. Reilly | Emory University School of Nursing | None | None | None | None | None | None | None |
| Neil L. Weintraub | Medical College of Georgia at Augusta University | NIH (AR070029, HL134354, HL126949, HL142097)† | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.